Holen Sie sich die Stockscreener-App
15.98
1.66%
-0.27
Handel nachbörslich:
15.98
Schlusskurs vom Vortag:
$16.25
Offen:
$16.03
24-Stunden-Volumen:
594.10K
Relative Volume:
1.14
Marktkapitalisierung:
$871.91M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-6.00%
1M Leistung:
-6.22%
6M Leistung:
+10.21%
1J Leistung:
-33.44%
1-Tages-Spanne:
$15.49
$16.65
1-Wochen-Bereich:
$15.42
$17.71
52-Wochen-Spanne:
$7.80
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Firmenname
Bicara Therapeutics Inc
Sektor
Branche
Telefon
617-468-4219
Adresse
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Vergleichen Sie BCAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
15.98 | 887.45M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-05-23 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | Eingeleitet | Wells Fargo | Underweight |
| 2025-02-06 | Eingeleitet | Wedbush | Outperform |
| 2024-12-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-05 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-10-08 | Eingeleitet | Stifel | Buy |
| 2024-10-08 | Eingeleitet | TD Cowen | Buy |
Alle ansehen
Bicara Therapeutics Inc Aktie (BCAX) Neueste Nachrichten
What risks investors should watch in Bicara Therapeutics Inc. stockPortfolio Return Report & Weekly High Momentum Picks - newser.com
Real time alert setup for Bicara Therapeutics Inc. performanceEarnings Growth Report & Risk Controlled Daily Plans - newser.com
What dividend safety score for Bicara Therapeutics Inc. stockJuly 2025 EndofMonth & Low Drawdown Momentum Ideas - newser.com
Why Bicara Therapeutics Inc. stock appeals to analystsWeekly Trade Review & Safe Entry Trade Signal Reports - newser.com
Is Bicara Therapeutics Inc. stock a buy before product launchesFed Meeting & Safe Capital Growth Stock Tips - newser.com
How Bicara Therapeutics Inc. stock benefits from global expansion2025 Bull vs Bear & Risk Controlled Stock Pick Alerts - newser.com
Is Bicara Therapeutics Inc. stock safe for conservative investors2025 Short Interest & Reliable Momentum Entry Alerts - newser.com
How to manage a losing position in Bicara Therapeutics Inc.Jobs Report & Technical Pattern Based Buy Signals - newser.com
How currency fluctuations impact Bicara Therapeutics Inc. stock2025 AllTime Highs & Low Drawdown Investment Strategies - newser.com
Analyzing Bicara Therapeutics Inc. with risk reward ratio charts2025 Macro Impact & AI Driven Stock Movement Reports - newser.com
Will Bicara Therapeutics Inc. stock see insider buyingSell Signal & Verified Stock Trade Ideas - newser.com
How Bicara Therapeutics Inc. stock compares to market leadersJuly 2025 Rallies & Stepwise Trade Signal Implementation - newser.com
Why Bicara Therapeutics Inc. stock is considered a top pickTrade Ideas & Safe Capital Preservation Plans - newser.com
How institutional buying supports Bicara Therapeutics Inc. stockPortfolio Update Report & Verified Momentum Stock Alerts - newser.com
Will Bicara Therapeutics Inc. stock benefit from automationJuly 2025 Short Interest & Safe Capital Growth Trade Ideas - newser.com
What institutional flow reveals about Bicara Therapeutics Inc.Earnings Beat & Risk Controlled Stock Alerts - newser.com
Finanzdaten der Bicara Therapeutics Inc-Aktie (BCAX)
Es liegen keine Finanzdaten für Bicara Therapeutics Inc (BCAX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):